Allergy. European Journal of Allergy and Clinical Immunology, 2020 Dupilumab, a fully human monoclonal antibody against interleukin‐4 receptor α, is approved as add‐on maintenance treatment for inadequately controlled type 2 severe asthma.
I. Agache +33 more
semanticscholar +1 more source
Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma : results from two phase 3, randomised, double-blind, placebo-controlled trials [PDF]
, 2020 BACKGROUND: Reslizumab 3 mg/kg administered intravenously is approved for the treatment of severe eosinophilic asthma. We assessed the safety and efficacy of subcutaneous reslizumab 110 mg in two trials in patients with uncontrolled severe asthma and ...
Adir, Yochai +13 more
core +1 more source
Respiratory Medicine Case Reports, 2021 Severe eosinophilic asthma is associated with a heavy burden and impact on daily living in patients experiencing uncontrolled symptoms, exacerbations, and treatment side effects.
John Davison, Simon Doe
doaj
Different endotypes and phenotypes drive the heterogeneity in severe asthma
Allergy. European Journal of Allergy and Clinical Immunology, 2020 The identification of sputum eosinophilia indicating corticosteroid responsiveness in subjects with severe asthma heralded the beginning of phenotyping asthmatic subjects based on airways inflammation.
P. McDowell, L. Heaney
semanticscholar +1 more source
Asthma diagnosis and treatment - 1012. The efficacy of budesonide in the treatmetn of acute asthma in children: a double-blind, randomized, controlled trial. [PDF]
, 2013 Background Current evidence suggests that inhaled glucocorticoids (IGC) have a more profound topical none genomic effect on bronchial airways as compared to systemic glucocorticoids.
Al-Ghamdi, N +7 more
core +1 more source
Allergy. European Journal of Allergy and Clinical Immunology, 2020 Allergic asthma is a frequent asthma phenotype. Both IgE and type 2 cytokines are increased, with some degree of overlap with other phenotypes. Systematic reviews assessed the efficacy and safety of benralizumab, dupilumab and omalizumab (alphabetical ...
I. Agache +33 more
semanticscholar +1 more source
Pharmacotherapy of severe asthma [PDF]
Current Opinion in Pharmacology, 2010 Severe asthma is a complex and heterogeneous phenotype where management can be challenging. While many patients with severe asthma respond to high-dose inhaled corticosteroids in combination with a long-acting beta-agonist, there remains a significant subset of patients that require oral corticosteroids to control symptoms.
Monica Kraft, Rafael Firszt
openaire +3 more sources
Bronchial thermoplasty : a new therapeutic option for the treatment of severe, uncontrolled asthma in adults [PDF]
, 2014 Bronchial thermoplasty is a young yet promising treatment for severe asthma whose benefit for long-term asthma control outweighs the short-term risk of deterioration and hospitalisation in the days following the treatment.
Alagha, Khuder +10 more
core +5 more sources
Experience with mepolizumab in adults with severe eosinophilic asthma: a case series from India
Respirology Case Reports, 2021 Severe asthma can be associated with eosinophilic or allergic phenotypes or both. Eosinophilic inflammation is associated with exacerbations and disease severity due to biological activity of interleukin‐5 (IL‐5).
Venkata Nagarjuna Maturu +7 more
doaj +1 more source
COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry
European Respiratory Journal, 2020 Epidemiological studies suggest that patients with asthma are not at an increased risk of severe coronavirus disease 2019 (COVID-19) caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1–3].
S. Hanon +11 more
semanticscholar +1 more source